These findings support the claim that Medicare Advantage (MA) payments may be driven more by diagnosis and coding practices ...

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, analyzes the Bimzelx Navigate program, a ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

The Southern Rural Black Women’s Initiative for Economic and Social Justice works to overcome race, class, cultural, ...

Long-term yogurt consumption is associated with a reduced risk of Bifidobacterium-positive colorectal cancer, particularly in ...

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

Panelists discuss how biosimilars are gaining traction through targeted education, cost-effectiveness analysis, and rigorous ...

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer ...

Panelists discuss how health care professionals have varying confidence in biosimilars, driven by concerns about efficacy, safety, and interchangeability. Increased education, real-world evidence, ...